-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
The 110th Approved Generic Drug! Shijiazhuang Sihua Pharmaceutical Group’s Deferiprone Dispersible Tablets Have Been Approved
Category:
发布时间：2024-12-11
【概要描述】
Continuous innovation fuels sustained development. On December 10, Shijiazhuang Sihua Pharmaceutical Group received registration approval from the National Medical Products Administration for its Class 4 chemical drug—deferasirox dispersible tablets (125 mg)—which is deemed to have passed the bioequivalence evaluation, making it the group’s 110th product to either pass or be deemed to have passed such an evaluation.
Innovation never stops, and development gains new momentum. On December 10, Shijiazhuang Sihua Pharmaceutical Group’s application for Class 4 chemical drug—Deferasirox Dispersible Tablets (125 mg)—received registration approval from the National Medical Products Administration and was deemed to have passed the consistency evaluation, making it the group’s 110th product to either pass or be deemed to have passed such an evaluation.
According to reports, deferasirox is primarily indicated for the treatment of chronic iron overload resulting from frequent blood transfusions in β-thalassemia patients aged 2 years and older, as well as for the management of chronic iron overload in non-transfusion-dependent thalassemia syndromes in patients aged 10 years and older. This iron-chelating agent was developed by Novartis of Switzerland and represents the first orally administered iron chelator approved by the U.S. Food and Drug Administration for routine use; it was approved for marketing in China in 2010.
According to data from MeneNet, sales at the end-user level—covering urban public hospitals, county-level public hospitals, urban community health centers, and township health clinics—in China reached RMB 160.54 million in 2023, with sales exceeding RMB 84.08 million in the first half of 2024, demonstrating a sustained growth trend.
Shijiazhuang Fourth Pharmaceutical Group steadfastly pursues an R&D strategy that integrates generic drug development with innovative research. Leveraging a robust innovation team, a well-established innovation platform, and mature research mechanisms, the company adopts targeted, strategic initiatives and relentlessly drives innovation with a relentless, forward-moving momentum. As a result, its product pipeline has become increasingly clear, R&D achievements have accumulated steadily and begun to yield significant results, creating a seamless value chain and fostering synergistic clusters of capabilities. The depth of its product portfolio continues to grow, and its R&D quality and efficiency remain at the forefront of the national pharmaceutical industry. To date, a total of 110 drug varieties comprising 145 dosage forms have either passed or been deemed to have passed the evaluation of generic drug quality and therapeutic equivalence, demonstrating the company’s vibrant vitality through a continuously optimized product mix and providing strong impetus for market competition and enhanced product accessibility.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091